Programs & products

Enrollment in the first-in-human trial of IPH4102 in relapsed/refractory cutaneaous T-cell lymphomas (CTCL) is proceeding with no dose-limiting toxicities to date; Dose level 9 out of 10 is currently...

Preliminary results from the dose-escalation part of Phase I study in patients with relapsed/refractory cutaneous T-cell lymphomas Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH)...

The combination of lirilumab and nivolumab in a phase I study of advanced solid tumors showed no added toxicity over nivolumab monotherapy; Data supports ongoing Phase I cohort expansion of lirilumab...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces that safety data for two Phase I studies of lirilumab in combination with nivolumab or ipilimumab conducted by...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announced that the Data and Safety Monitoring Board (“DSMB”) completed its seventh assessment of the EffiKIR study and...

Phase I study of IPH4102 in patients with relapsed/refractory cutaneous T-cell lymphomas commenced in November 2015 and continues on track in EU and US centers Innate Pharma SA (the “Company” -...

Update on strategy and pipeline Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and...

Novel, potent anti-CD39 antibody, IPH52, validated in preclinical models. Innate Pharma and OREGA Biotech today presented preclinical data on IPH52, a new CD39 checkpoint inhibitor program, at the...

Preclinical data demonstrate enhanced anti-tumor efficacy by combining PD-1/PD-L1 pathway blockade and NKG2A checkpoint inhibitor; Resistance to PD-1 pathway blockers is associated with upregulation...

Novel antibodies identified that block the CD73 immune checkpoint for cancer immunotherapy; Strengthens Innate’s positioning in targeting the tumor microenvironment. Innate Pharma SA (the “Company” -...